Study Of Df9001 In Patients With Advanced Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Jennifer Leddon
- Specialties:
- Type of Study: Drug
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors.
Criteria:
Null
Keywords:
Solid Tumors
For More Information:
Kayla Webb
NULL
cancer@uchealth.com